25-07-2018
sprng23 / iStockphoto.com
Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CJEU, Court of Justice of the European Union, SPC, Truvada, Teva, Accord Healthcare, Lupin, Mylan, Gilead, patent, supplementary protection certificate
CJEU hands down SPC guidance in Royalty Pharma
30-04-2020
German patent court publishes reasoning in Gilead SPC dispute
06-11-2018
SPC waiver proposal could discourage innovation, says pharma group
09-08-2018
AG opines on ‘thorny issue’ in Truvada SPC clash
25-04-2018
English High Court refers Truvada SPC case to CJEU
16-01-2017
